Skip to main content

Dr. Cynthia Denu-Ciocca, an Associate Professor of Medicine in UNC’s Division of Nephrology, has been selected to serve on the editorial board of the American Society of Nephrology’s (ASN) Education Program.

Dr. Denu-Ciocca is one of 14 national nephrologist clinicians to serve on the ASN Kidney Self-Assessment Program (KSAP) board, which sets the editorial direction for continuing medical education. She was selected for the editorial board after contributing top, case-based questions to the ASN’s KSAP, an online self-assessment program that provides the essentials of nephrology for fellows preparing for initial certification, practicing nephrologists preparing for recertification, and practitioners who want to refresh their clinical knowledge, diagnostic, and therapeutic skills.

“As the field of nephrology continues to advance, it’s a privilege to represent UNC as a member of this editorial board, promoting continuing education that strengthens the knowledge, diagnostic reasoning, and clinical judgment skills of the certified nephrologist,” said Dr. Denu-Ciocca.

The KSAP question and answer study tool is self-paced, giving a clinician the ability to make appropriate diagnostic and management decisions that have important consequences for patients. The exam requires recognition of common as well as rare clinical problems for which patients may consult a certified nephrologist.

“We all want the best for our patients,” said Dr. Denu-Ciocca. “It’s very rewarding to be able to help fellow clinicians expand their understandings and professional skills while they are providing services to patients.”

Dr. Denu-Ciocca came to UNC as a resident and fell in love with nephrology. She is now the director of the Carolina Dialysis Centers located in Carrboro and Pittsboro, where she oversees the management of patients with end stage kidney disease. She is also the nephrology course director for third and fourth year medical students. She specializes in the medical management of kidney stones, participates in clinical trials in the end stage renal disease population and has a strong interest in pregnancy and kidney disease.